About Hookipa Pharma (HOOK)

Hookipa Pharma Inc (HOOK) is a biotechnology company that focuses on developing immunotherapies to combat infectious diseases and cancers. The company is headquartered in New York, New York, and was founded in 2011. Hookipa Pharma is a clinical-stage company that is leveraging its proprietary Vaxwave technology platform to develop a new class of immunotherapeutics called arenaviral-based vectors (ABVs). ABVs are designed to stimulate a targeted and long-lasting immune response against specific antigens. These antigens can be derived from infectious pathogens, including viruses, or tumor antigens. By harnessing the power of the immune system, Hookipa Pharma aims to provide effective and durable treatments for patients with unmet medical needs.

One of the key advantages of Hookipa Pharma's technology is its ability to induce a strong and specific immune response. Unlike traditional vaccines, which often rely on weakened or inactivated pathogens, Hookipa Pharma's ABVs deliver viral antigens directly to immune cells. This targeted approach can stimulate a more robust immune response and potentially improve the efficacy of the treatment. Additionally, Hookipa Pharma's ABVs can trigger both the humoral immune response (involving antibodies) and the cellular immune response (involving T cells). This dual mechanism of action may be particularly beneficial in treating diseases where both antibody and T cell responses are required for effective immune control.